Skip to main content

Market Overview

Pfizer To Make COVID-19 Jab In India On Faster Clearance Assurance, Export Freedom: Reuters


Pfizer Inc (NYSE: PFE) has told the Indian government it wants to produce its COVID-19 vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports, reports Reuters.

  • Last month, the company pulled out its marketing application seeking emergency approval for its COVID-19 shot in India after failing to adhere to the drug regulator’s request for a small local study.
  • Pfizer was the first company to apply for emergency use authorization in India, proposing to import doses from its U.S. and European facilities instead of producing locally.
  • “U.S. companies want to produce vaccines in India under joint ventures,” said one of the sources, citing Pfizer and fellow U.S. drug maker Moderna Inc (NASDAQ: MRNA).
  • Another source confirmed Pfizer was interested in manufacturing in India, but Reuters could not find a second confirmation on Moderna.
  • The Serum Institute of India is the world’s largest vaccine maker and is already bulk-manufacturing the Oxford University/AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine and plans to start producing the Novavax Inc (NASDAQ: NVAX) shot from next month.
  • Price Action: PFE shares are up 0.7% at $34.69, and BNTX shares gained 2.74% at $99.12 in market trading on the last check Wednesday.

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: COVID-19 Vaccine IndiaBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at